Labcorp Holdings Inc. (LH) Financial Ratios

Labcorp Holdings Inc. (LH) has an ST Score of 45.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate LH a Buy, with a price target of $340.75 (+10.3% vs the current price). Our ST Score grades it C+ (45.2/100). The ST Score is a data-driven signal, not a recommendation.

Valuation D+, Profitability A, Financial Strength D+, Momentum D+, Growth D+, Forecast C+, Sentiment C+.

Labcorp Holdings Inc. (LH) earns a valuation grade of D+, measured against Medical - Diagnostics & Research peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Labcorp Holdings Inc. (LH) earns a growth grade of D+, measured against Medical - Diagnostics & Research peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Labcorp Holdings Inc. (LH) earns a profitability grade of A, measured against Medical - Diagnostics & Research peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Labcorp Holdings Inc. (LH) earns a financial strength grade of D+, measured against Medical - Diagnostics & Research peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Labcorp Holdings Inc. (LH) is $340.75 from 35 analysts, which is +10.3% versus the recent price of $308.95.

Labcorp Holdings Inc. (LH) has a Piotroski F-Score of 8 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.